LEXINGTON, Mass. – T2 Biosystems, Inc., a company developing next-generation medical diagnostic products, today announced that it has relocated to a newly renovated 20,000 sq.ft. facility located in Lexington, MA.

T2 Biosystems’ new facility in Lexington is more than twice the size of the company’s existing space in

Cambridge, and the new space will accommodate the growth in the business being driven by partner

and commercial product development. The new facility includes state-of-the-art laboratories to support

assay and instrument development, as well as facilities to support commercialization of the company’s

novel diagnostic tests and systems. The increased capacity in a highly desirable location enables T2

Biosystems to continue to attract and provide support for the company’s highly-skilled staff of scientists, engineers, and business professionals.

“In 2010, the T2 Biosystems team significantly advanced the development of our company’s proprietary

detection system. We now have robust and compelling data that validates our ability to provide central

lab quality results for a broad set of diagnostic tests that today cannot be run in a decentralized setting,” said John McDonough, President and Chief Executive Officer. “The new space will enable us to expand our capabilities and accelerate product development for us and our partners. We believe this new facility will afford us the flexibility to accommodate our future growth, as we make progress toward our goal of establishing the T2 detection technology as a new standard in the diagnostics industry.”

The facility being newly-occupied by T2 Biosystems is adjacent to Route 95 and is easily accessible from Hanscom Field in Bedford, MA and Logan Airport in Boston, MA. The new site enables T2 Biosystems to also retain a close proximity to the company’s founders at the Massachusetts Institute of Technology and Harvard University. T2 Biosystems’s new address is 101 Hartwell Avenue, Lexington, MA 02421.

About T2 Biosystems

T2 Biosystems is a private biotechnology company developing next-generation medical diagnostic

products using its proprietary detection technology, combining nanotechnology and miniaturized

magnetic resonance (MR) technology to eliminate sample preparation and provide rapid, accurate and

portable diagnostics for assays that cannot be performed in decentralized settings. T2 Biosystems was founded in 2006 by renowned researchers from the Massachusetts Institute of Technology, Harvard University, Harvard Medical School and Massachusetts General Hospital, and has assembled a worldclass team, board of directors and scientific advisory board that collectively have a proven track record of translating technologic innovations into breakthrough products, building significant corporate value.

T2 Biosystems is located in Lexington, Massachusetts. For more information, please visit the company’s

www.t2biosystems.com.